NCT05189821 RFA Treatment for Papillary Thyroid Microcarcinoma
| NCT ID | NCT05189821 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Columbia University |
| Condition | Papillary Thyroid Microcarcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2021-11-01 |
| Primary Completion | 2027-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2021-11-01 with a primary completion date of 2027-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Thyroid surgery has always been the mainstay of treatment for thyroid cancer. Thyroid surgery carries a low risk of complications that include recurrent or superior laryngeal nerve injury leading to voice changes, hypoparathyroidism, hypothyroidism with need for thyroid hormone supplementation, and unsightly scarring. Although many patients with thyroid cancer find these risks acceptable, these risks are sometimes less acceptable to patients with benign disease. In an era when the medical field is treating thyroid diseases less aggressively, there is a pressing need to identify approaches to treat indolent malignant disease less invasively. The purpose of this observational study is to evaluate the efficacy and safety of Radiofrequency Ablation (RFA) for treatment of Papillary Thyroid Microcarcinoma (PTMC) in patients that have already agreed to RFA procedure based on treating physician recommendation. This is a data collection study in which we ask participants to give us access to information generated before and after RFA treatment of their condition. The RFA procedure uses image guidance to place an electrode through the skin into the target tumor. In RFA, high-frequency electrical currents are passed through an electrode, creating a small region of heat to treat the lesion.
Eligibility Criteria
Inclusion Criteria: * Adult patients (\>/= 18 years) * Biopsy proven papillary thyroid microcarcinoma (\>/= 1.5cm in greatest diameter, PTMC) * Either refuse surgery or are not good surgical candidates Exclusion Criteria: * Cardiac arrhythmia * Pregnancy
Contact & Investigator
Jennifer H Kuo, MD MS
PRINCIPAL INVESTIGATOR
Columbia University
Frequently Asked Questions
Who can join the NCT05189821 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Papillary Thyroid Microcarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05189821 currently recruiting?
Yes, NCT05189821 is actively recruiting participants. Contact the research team at jhk2029@cumc.columbia.edu for enrollment information.
Where is the NCT05189821 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT05189821 clinical trial?
NCT05189821 is sponsored by Columbia University. The principal investigator is Jennifer H Kuo, MD MS at Columbia University. The trial plans to enroll 50 participants.